滚动资讯
FierceBiotechApogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clearFierceBiotechSanofi returns to T-cell engager territory with $1.2B pact for phase 1-stage trispecificFierceBiotechFDA solicits feedback on controversial national priority voucher review pathwayFierceBiotechNovartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&DFierceBiotechStryker continues to bring hacked systems back online after patients delay surgeriesEndpoints NewsWuXi AppTec’s bet on the US pays off as revenues dip elsewhereEndpoints NewsFormer Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech OryonBioWorldBiggest gainers and losers for March 16-20, 2026BioPharma DiveFDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed sharesEndpoints NewsCEO and C-suite are out in battle for control of AuriniaEndpoints NewsDizal's first-line lung cancer data; Sanofi expands in ChinaPharmaVoiceHow AI is reshaping clinical trials
BioWorld 2026年1月13日

艾伯维以潜在50亿美元交易获得Remegen的PD-1/VEGF双特异性抗体。

艾伯维以潜在50亿美元交易获得Remegen的PD-1/VEGF双特异性抗体。

原文
暂时没有全文，请查看原始来源。

目录

59 全部